Customization of Special Chemical Raw Materials in The Pharmaceutical Intermediate Industry

Customer Requirements: 

A well-known pharmaceutical company needs a special structured chemical raw material as an intermediate when developing a new anti-cancer drug. This raw material not only needs to have extremely high purity (over 99.9%), but also has extremely strict restrictions on the types and contents of impurities. At the same time, the production process is required to meet the GMP standards of the pharmaceutical industry to ensure the stability of product quality and consistency between batches.

Customized Solution: 

We have formed a specialized research and development team composed of senior chemical experts and quality control experts in the pharmaceutical industry. After multiple rounds of experiments and optimization on the raw material synthesis route, a new synthesis process has been determined that can effectively reduce side reactions and improve the purity of the target product. In the production process, a clean production workshop that meets GMP standards has been established, and equipment has been specially modified to achieve full process automation control, precise control of reaction conditions (such as temperature, pressure, reaction time), and ensure stable quality of each batch of products. At the same time, advanced detection equipment and technology are introduced to conduct multiple strict inspections on raw materials from feeding to finished product shipment, ensuring that the impurity content is below the prescribed standards.

Implementation Effect: 

Successfully customized special chemical raw materials that meet the requirements for customers. Through customer verification in the drug development process, the purity of the raw material has remained stable at over 99.95%, with impurity content far below industry standards, effectively promoting the development process of anti-cancer drugs. The product has good stability between batches, providing reliable guarantees for customers' large-scale drug clinical trials. Customers highly recognize customized services, and the two parties have established a long-term strategic partnership to jointly explore more customized needs for pharmaceutical intermediates and help promote innovative development in the pharmaceutical industry.